BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21763093)

  • 1. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
    Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
    Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?
    Schechner V; Nobre V; Kaye KS; Leshno M; Giladi M; Rohner P; Harbarth S; Anderson DJ; Karchmer AW; Schwaber MJ; Carmeli Y
    Clin Infect Dis; 2009 Mar; 48(5):580-6. PubMed ID: 19191643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
    Tuon FF; Gortz LW; Rocha JL
    Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
    Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa bloodstream infections: how should we treat them?
    van Delden C
    Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S71-5. PubMed ID: 17698326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
    Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
    Lee CC; Lee CH; Hong MY
    Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.
    Peña C; Suarez C; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Oliver A; Martínez-Martínez L;
    Clin Infect Dis; 2013 Jul; 57(2):208-16. PubMed ID: 23580739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
    Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
    Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.
    Vidal F; Mensa J; Almela M; Martínez JA; Marco F; Casals C; Gatell JM; Soriano E; Jimenez de Anta MT
    Arch Intern Med; 1996 Oct; 156(18):2121-6. PubMed ID: 8862105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
    Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor?
    Chen SC; Lawrence RH; Byth K; Sorrell TC
    Med J Aust; 1993 Nov; 159(9):592-7. PubMed ID: 8232033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
    Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
    Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.
    Degoricija V; Sharma M; Legac A; Gradiser M; Sefer S; Vucicević Z
    Croat Med J; 2006 Jun; 47(3):385-97. PubMed ID: 16758516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
    Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
    J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.